Asia Pacific Multiple Hereditary Exostosis Market
市场规模（十亿美元）
CAGR :
% 
USD
22.90 Million
USD
33.33 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 22.90 Million |
 Market Size (Forecast Year) |
USD 33.33 Million |
 CAGR |
% |
| Major Markets Players |
|
亞太地區多發性遺傳性外生骨疣市場細分，按類型（無蒂和帶蒂）、治療（手術、藥物及其他）、診斷（X 光、電腦斷層掃描 (CT)、磁振造影 (MRI)、基因檢測及其他）、部位（腿、手臂、肩膀、骨盆、手指和腳趾）、年齡組（兒童和成人診所）、最終用戶（兒童和成人診所）
亞太多發性遺傳性外生骨疣市場規模
- 2024 年亞太多發性遺傳性外生骨疣市場規模為2,290 萬美元 ，預計 到 2032 年將達到 3,333 萬美元，預測期內 複合年增長率為 4.80%。
- 市場成長主要得益於該地區新興經濟體對罕見遺傳疾病的認識和早期診斷的提高、專業醫療保健服務的改善以及基因篩檢計畫的增加。
- 此外，精準醫療投資的不斷增長、政府的支持性舉措以及兒科患者人數的不斷增加，正在推動對先進治療方案的需求不斷增長。這些因素共同加速了診斷和治療解決方案的普及，顯著促進了該行業的成長。
亞太多發性遺傳性外生骨疣市場分析
- 多發性遺傳性外生骨疣 (MHE) 是一種罕見的遺傳性疾病，其特徵是良性骨腫瘤。由於人們的認識不斷提高、診斷能力不斷提高以及城市中心地區專科骨科和遺傳服務日益普及，該疾病在亞太地區正受到越來越多的臨床關注。
- 早期診斷和先進治療幹預的需求不斷增長，主要得益於醫療基礎設施的改善、政府對罕見疾病管理的支持以及中國、日本和印度等國家基因篩檢計畫的擴展
- 中國在亞太多發性遺傳性外生骨疣市場佔據主導地位，2024 年的收入份額最高，為 39.9%，這得益於兒科患者人數的不斷增長、基因組醫學的進步以及專注於骨骼發育不良的區域卓越中心的存在
- 受罕見疾病政策加強、臨床試驗活動擴大以及患者權益組織作用增強的推動，印度預計將在預測期內成為亞太地區多發性遺傳性外生骨疣市場成長最快的國家
- 2024 年，無蒂骨疣在亞太地區多發性遺傳性外生骨疣市場中佔據主導地位，市場份額為 59.1%，這是因為無蒂骨疣在關節附近發病率較高，且更有可能造成神經壓迫，因此需要更早的臨床檢測和乾預
報告範圍和亞太多發性遺傳性外生骨疣市場細分
|
屬性 |
亞太地區多發性遺傳性外生骨疣關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
亞太
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
亞太地區多發性遺傳性外生骨疣市場趨勢
“基因診斷和個人化治療方法的進展”
- 亞太地區多發性遺傳性外生骨疣 (MHE) 市場的一個顯著且加速發展的趨勢是先進基因診斷工具的日益整合，以及針對兒童骨骼發育不良患者特定需求的個人化治療方案的出現。這一趨勢有助於提高早期發現率，並促成有針對性的干預策略。
- 例如，日本和中國等國家越來越多地使用新一代定序 (NGS) 技術來識別 EXT1 和 EXT2 基因突變，使臨床醫生能夠早期準確地診斷 MHE。遺傳諮詢也正在成為專科骨科和兒科診所的常見做法。
- 低輻射CT和高解析度MRI等非侵入性影像技術的日益普及，使得更好地監測外生骨疣的進展並有助於制定手術計劃。結合AI輔助的放射學分析，這些工具能夠提供更精確的病變追蹤和個人化治療方案。
- 這些診斷方法的進步，加上城市中心加強的公共衛生意識宣傳活動和篩檢項目，正在推動人們轉向主動管理疾病，而不是僅在出現併發症後才進行被動的手術幹預
- 該地區的患者登記和跨境合作正在增多，韓國和澳洲等國家參與了罕見疾病網絡，促進了MHE的臨床研究和數據共享。這些措施有助於形成針對特定地區的流行病學見解，並促進實證醫療。
- 對早期識別和個人化護理的日益關注正在改變亞太地區 MHE 治療的格局，為醫療創新和以患者為中心的骨科解決方案的提供創造平台
亞太多發性遺傳性外生骨疣市場動態
司機
“早期診斷的提高和兒科骨科服務的擴展”
- 亞太主要經濟體兒科骨科專科護理和診斷基礎設施的日益普及，是MHE市場成長的重要驅動力。透過基因篩檢實現的早期發現以及先進影像技術的應用不斷提升，使得早期幹預和更好的疾病治療效果成為可能。
- 例如，印度和中國在政府主導下，將罕見疾病納入國家衛生計劃，這促使MHE被納入三級醫院的診斷小組，從而提高了病例識別率。此外，國家罕見疾病登記處也正在建設中，以監測長期療效。
- 隨著臨床醫生和家庭意識的提升，對畸形手術矯正和疼痛管理服務的需求日益增長，尤其是在兒科醫院和骨科中心。機器人輔助手術平台和3D列印骨骼建模技術正越來越多地被應用於外生骨疣的精準切除。
- 該地區罕見疾病支持組織的興起也幫助患者及其家庭取得資源，推動更完善的照護方案，並協助他們與專科醫生建立聯繫。這些努力正在促進罕見疾病的早期參與和綜合治療。
克制/挑戰
“農村地區認知度低，獲得專門治療的機會有限”
- 儘管城市醫療中心取得了進展，但全科醫生對MHE的認知度有限，以及農村或偏遠地區基因診斷設施的匱乏，仍然是MHE廣泛滲透市場的主要障礙。由於疾病罕見且症狀複雜，許多病例未能確診或被誤診。
- 在醫療基礎設施較弱的國家（例如東南亞部分地區），患者可能無法及時獲得骨科專家的診治，或可能缺乏進行基因檢測和後續影像檢查的經濟能力，從而導致治療不足或可避免的併發症
- 此外，缺乏標準化的治療指南和支離破碎的轉診系統，使得患者難以獲得多學科治療。儘管亞太地區一些國家正在採取措施改善罕見疾病政策框架，但實施情況仍參差不齊。
- 為了克服這些挑戰，增加對農村醫療保健的投資、用於骨科諮詢的遠距醫療平台、補貼基因篩檢計畫以及罕見疾病臨床醫生培訓至關重要。政府、非政府組織和醫療機構之間的合作對於彌合醫療可及性差距並確保整個地區的MHE患者獲得公平的醫療服務至關重要。
亞太多發性遺傳性外生骨疣市場範圍
市場根據類型、治療、診斷、部位、年齡層和最終用戶進行細分
- 按類型
根據類型，亞太地區多發性遺傳性外生骨疣市場分為無蒂型和帶蒂型。無蒂型佔據市場主導地位，2024 年收入份額最高，達 59.1%，這得益於其基底寬闊且靠近神經和關節等重要結構，臨床可見度更高。這些特徵通常可使症狀出現更早、診斷率更高，且對手術介入的需求也更大。無蒂型病灶也較常伴隨功能障礙和畸形，因此需要及時進行骨科評估。
預計到2032年，帶有蒂骨疣的診療將以最快的速度增長，這得益於成像技術的進步，使其能夠更準確地檢測長柄外生骨疣，以及非侵入性監測技術的日益普及。隨著人們認知度的提高以及放射學工具在門診的普及，症狀較輕的帶蒂骨疣的檢出率也將大幅提升。
- 按治療
根據治療方案，亞太地區多發性遺傳性外生骨疣市場細分為手術、藥物治療和其他治療。由於手術在治療神經壓迫、肢體畸形或關節活動受限等併發症方面發揮關鍵作用，其市場份額在2024年達到46.7%，位居第一。兒科患者通常接受外生骨疣手術切除，以預防生長異常或慢性疼痛。日本、中國和韓國等國家擁有經驗豐富的骨科醫生以及機器人輔助手術和3D建模等先進工具，這為該領域的成長提供了支持。
預計2025年至2032年期間，藥物領域將出現最快的複合年增長率，主要用於術後疼痛管理和發炎控制。臨床上對旨在減少外生骨疣生長的標靶療法的興趣也日益濃厚，儘管此類療法目前大多仍處於研究階段。
- 按診斷
根據診斷方式，亞太地區多發性遺傳性外生骨疣市場細分為X光、電腦斷層掃描 (CT)、磁振造影 (MRI)、基因檢測等。 X射線憑藉其成本效益高、普及性強以及能夠高效識別多發性遺傳性外生骨疣 (MHE) 特徵性骨質增生的優勢，在2024年佔據診斷領域的主導地位，市場份額最高，為34.2%。在大多數臨床環境中，X射線仍然是首選的影像學檢查工具。
預計到2032年，基因檢測將以最快的速度成長，因為它可以透過EXT1和EXT2基因分析來確認遺傳模式。隨著新一代定序（NGS）的普及和認知度的提高，尤其是在城市醫療中心，基因檢測對於早期診斷和家庭諮詢至關重要。
- 按站點
根據病變部位，亞太地區多發性遺傳性外生骨疣市場可細分為腿部、手臂、肩膀、骨盆、手指和腳趾。 2024年，腿部外生骨疣的市佔率最高，達36.9%，這是因為外生骨疣常見於股骨、脛骨和腓骨附近，而這些部位在兒童中易受機械應力和生長障礙。由於步態異常或肢體長度差異，這些病變通常需要骨科評估和矯正手術。
預計在預測期內，手臂和肩膀將出現最快的增長，因為它們是常見的解剖部位，尤其是在兒科人群中，畸形會影響正常功能和運動範圍。
- 按年齡組
根據年齡組，亞太地區多發性遺傳性外生骨疣市場分為兒童和成人兩類。 2024年，兒童佔據主導地位，市場份額達72.1%，因為多發性遺傳性外生骨疣通常在兒童早期診斷，此時骨骼生長活躍，並開始出現可見腫塊、關節受限或肢體畸形等症狀。
雖然預計成人病例在 2025 年至 2032 年間將出現最快的複合年增長率，特別是由於診斷延遲或復發，但大多數幹預、篩檢和手術發生在兒童和青少年時期。
- 按最終用戶
根據最終用戶，亞太地區多發性遺傳性外生骨疣市場細分為醫院、專科診所、門診手術中心和其他類型。醫院憑藉其全面的診斷和手術能力（包括骨科手術、放射科和遺傳諮詢）在2024年佔據了48.3%的最大份額，佔據了該細分市場的最大份額。中國、日本和印度等國家的兒科醫院和大學附屬醫療中心是多發性遺傳性外生骨疣診斷和治療的主要中心。
由於人們對微創手術和日間手術的偏好日益增加，預計預測期內門診手術中心將呈現強勁成長。
亞太多發性遺傳性外生骨疣市場區域分析
- 中國在亞太多發性遺傳性外生骨疣市場佔據主導地位，2024 年的收入份額最高，為 39.9%，這得益於兒科患者人數的不斷增長、基因組醫學的進步以及專注於骨骼發育不良的區域卓越中心的存在
- 中國以及日本、印度等其他國家的患者和臨床醫生正在積極採用早期幹預策略、先進的手術技術和個人化的護理計劃，從而改善患者的治療效果並擴大市場
- 國家罕見疾病政策、醫療保健領域的公私合作夥伴關係以及正在進行的研究合作進一步推動了這一增長，使亞太地區成為 MHE 診斷和治療領域創新和臨床進展的領先地區
中國多發性遺傳性外生骨疣市場洞察
2024年，中國多發性遺傳性外生骨疣市場佔據亞太地區MHE市場39.9%的最大收入份額，這得益於其龐大的兒科人口、先進影像技術的日益普及以及城市醫院基因檢測管道的不斷擴大。國家罕見疾病策略以及基因組醫學領域投資的不斷增加，正在支持遺傳性骨骼疾病的早期診斷和管理。政府支持的篩檢計畫和專科骨科中心的存在，將繼續推動市場成長。
日本多發性遺傳性外生骨疣市場洞察
日本多發性遺傳性外生骨疣市場正經歷顯著成長，這得益於該國先進的醫療基礎設施和對精準醫療的重視。基因檢測與標準診斷流程的整合，加上日本積極的罕見疾病政策框架，使得更準確、更早發現多發性遺傳性外生骨疣成為可能。此外，研究機構與醫療機構之間的緊密合作也有助於改善治療方案和患者預後。
印度多發性遺傳性外生骨疣市場洞察
2024年，印度多發性遺傳性外生骨疣市場將在亞太地區多發性遺傳性外生骨疣市場中佔據相當大的份額，這得益於骨科專科醫生數量的增加、三級醫院診斷工具的改進以及公眾意識的提升。政府旨在識別罕見疾病的舉措，包括國家罕見疾病政策，正在提高早期診斷和手術治療的可及性。龐大的兒科人口和城市中心醫療基礎設施的不斷擴展，進一步支持了市場的成長。
亞太地區多發性遺傳性外生骨疣市場份額
亞太地區多發性遺傳性外生骨疣產業主要由知名公司主導，包括：
- Illumina公司（美國）
- 美敦力（愛爾蘭）
- Zimmer Biomet Holdings, Inc.（美國）
- 史賽克（美國）
- 西門子醫療股份公司（德國）
- GE醫療科技公司（美國）
- 佳能醫療系統株式會社（日本）
- Esaote SpA（義大利）
- 賽默飛世爾科技公司（美國）
- 羅氏控股公司（瑞士）
- Koninklijke Philips NV（荷蘭）
- B.Braun Melsungen AG（德國）
- 安捷倫科技公司（美國）
- 珀金埃爾默公司（美國）
- 富士軟片株式會社（日本）
- 北京華大基因（BGI Genomics）（中國）
- 深圳邁瑞生物醫療電子股份有限公司 (中國)
- 江蘇特勞泰克醫療科技有限公司 (中國)
- 東芝公司（日本）
- Takara Bio Inc.（日本）
亞太多發性遺傳性外骨疣市場的最新發展如何？
- 2024年5月，中國衛生部擴大了國家罕見疾病登記範圍，將多發性遺傳性外骨疣（MHE）納入其中，旨在改善各主要省份患者的早期診斷、治療可及性和長期監測。這項措施體現了中國對罕見疾病管理的策略性投入，以及其致力於利用集中式數據系統實現個人化患者照護和改善臨床療效的承諾。
- 2024年3月，日本國立兒童保健發展中心啟動了一項合作研究項目，重點研究針對MHE中EXT1和EXT2突變的基因編輯療法。該計畫由領先的大學和生物技術公司參與，標誌著日本在精準醫療和罕見骨骼疾病基因療法創新方面取得了重大進展。
- 2024年2月，印度醫學研究理事會（ICMR）批准資助一項全國性試點項目，重點針對疑似患有骨骼發育不良（包括骨髓增生異常綜合徵）的兒科患者進行基因篩檢。該計畫旨在加強早期診斷，提升公立醫院的診斷能力，並透過基因諮詢服務為家庭提供支援。
- 2024年1月，韓國首爾國立大學醫院開始進行AI輔助影像演算法的臨床試驗，旨在透過MRI和CT掃描解讀提高MHE診斷的準確性。這項進展凸顯了韓國致力於將人工智慧融入骨科診斷，以提高效率並減少診斷延誤的努力。
- 2023年12月，澳洲罕見疾病網絡 (ARDN) 宣布與多家兒童醫院合作，旨在規範MHE和其他骨骼疾病的治療方案。此次合作包括為醫療保健提供者提供培訓模組，以及開發集中式數位病患登記系統，以促進研究、臨床決策和政策制定。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE ANALYSIS - OBSERVATORY DATA
4.4 EPIDEMIOLOGY
5 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: REGULATIONS
5.1 REGULATION IN UNITED STATES: U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.1.1 REGULATION IN EUROPE: EUROPEAN MEDICINES AGENCY (EMA)
5.2 REGULATION IN ASIA-PACIFIC (JAPAN): PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA)
5.3 MEDICAL DEVICE STANDARDS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF GENETIC DISORDERS
6.1.2 GROWING PEDIATRIC POPULATION
6.1.3 DEVELOPMENT OF NOVEL THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST OF ADVANCED THERAPIES
6.2.2 LIMITED AVAILABILITY OF THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASE IN PATIENT CARE AND SUPPORT SYSTEMS
6.3.2 INCREASE IN THE NUMBER OF COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS ABOUT THE DISORDER
6.4.2 LACK OF DRUG APPROVALS ASSOCIATED WITH THE DISORDER
7 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SESSILE
7.3 PEDUNCULATED
8 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY
8.2.1 REMOVE THE TUMOR
8.2.2 LENGTHEN LIMBS
8.3 MEDICATION
8.3.1 HOSPITAL PHARMACIES
8.3.2 DRUGS STORES AND RETAIL PHARMACIES
8.3.3 ONLINE PHARMACIES
8.4 OTHERS
9 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 X-RAY
9.2.1 SESSILE
9.2.2 PEDUNCULATED
9.3 COMPUTED TOMOGRAPHY (CT) SCAN
9.3.1 SESSILE
9.3.2 PEDUNCULATED
9.4 MAGNETIC RESONANCE IMAGING (MRI)
9.4.1 SESSILE
9.4.2 PEDUNCULATED
9.5 GENETIC TESTS
9.5.1 SESSILE
9.5.2 PEDUNCULATED
9.6 OTHERS
9.6.1 SESSILE
9.6.2 PEDUNCULATED
10 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE
10.1 OVERVIEW
10.2 LEGS
10.3 ARMS
10.4 SHOULDERS
10.5 PELVIS
10.6 FINGERS
10.7 TOES
11 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 PEDIATRIC
11.3 ADULT
12 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.2.1 PRIVATE
12.2.2 GOVERNMENT
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 ASIA-PACIFIC MULTIPLE HEREDITY EXOSTOSIS MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 INDIA
13.1.4 AUSTRALIA
13.1.5 SOUTH KOREA
13.1.6 INDONESIA
13.1.7 NEW ZEALAND
13.1.8 MALAYSIA
13.1.9 THAILAND
13.1.10 TAIWAN
13.1.11 SINGAPORE
13.1.12 PHILIPPINES
13.1.13 VIETNAM
13.1.14 REST OF ASIA-PACIFIC
14 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 BAYERS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT UPDATES
16.2 HALEON GROUP OF COMPANIES
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BASF
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT UPDATES
16.4 VIATRIS INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT UPDATES
16.5 ACTIZAPHARMA
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT UPDATES
16.6 ADVACARE PHARMA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT UPDATES
16.7 AUROBINDO PHARMA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT TABLETS
16.8 HALEON GROUP OF COMPANIES
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT UPDATES
16.9 IPSEN BIOPHARMACEUTICALS, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT UPDATES
16.1 MALLINCKRODT
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT UPDATES
16.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT UPDATES
16.12 TAJ PHARMACEUTICALS LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT UPDATES
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 PIPELINE ANALYSIS - OBSERVATORY DATA
TABLE 2 PIPELINE ANALYSIS - INTERVENTIONAL DATA
TABLE 3 SALES DATA - 2024
TABLE 4 SALES DATA - 2023
TABLE 5 SALES DATA - 2022
TABLE 6 SALES DATA - 2021
TABLE 7 SALES DATA - 2020
TABLE 8 SALES DATA - 2019
TABLE 9 SALES DATA - 2018
TABLE 10 COST OF PALOVAROTENE
TABLE 11 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC SESSILE IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC PEDUNCULATED IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC LEGS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC ARMS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC SHOULDERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC PELVIS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC FINGERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC TOES IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC PEDIATRIC IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC ADULT IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC SPECIALTY CLINICS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 64 CHINA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 CHINA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 67 CHINA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 CHINA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 CHINA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 CHINA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 CHINA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 73 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 74 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 CHINA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 JAPAN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 JAPAN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 80 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 81 JAPAN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 JAPAN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 JAPAN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 JAPAN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 JAPAN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 87 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 88 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 89 JAPAN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 92 INDIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 INDIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 95 INDIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 INDIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 INDIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 INDIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 INDIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 101 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 102 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 103 INDIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 106 AUSTRALIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 AUSTRALIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 108 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 109 AUSTRALIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 AUSTRALIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 AUSTRALIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 AUSTRALIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 AUSTRALIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 114 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 115 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 116 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 117 AUSTRALIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 120 SOUTH KOREA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 SOUTH KOREA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 122 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 123 SOUTH KOREA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 SOUTH KOREA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 SOUTH KOREA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 126 SOUTH KOREA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 127 SOUTH KOREA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 128 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 129 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 130 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 131 SOUTH KOREA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 134 INDONESIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 INDONESIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 136 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 137 INDONESIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 INDONESIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 INDONESIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 INDONESIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 INDONESIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 143 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 144 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 145 INDONESIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 148 NEW ZEALAND SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 NEW ZEALAND MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 150 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 151 NEW ZEALAND X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 NEW ZEALAND COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 NEW ZEALAND MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 NEW ZEALAND GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 NEW ZEALAND OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 156 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 157 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 158 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 159 NEW ZEALAND HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 162 MALAYSIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 MALAYSIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 164 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 165 MALAYSIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 MALAYSIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 MALAYSIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 MALAYSIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 MALAYSIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 171 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 172 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 173 MALAYSIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 176 THAILAND SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 THAILAND MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 178 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 179 THAILAND X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 THAILAND COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 THAILAND MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 182 THAILAND GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 183 THAILAND OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 184 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 185 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 186 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 187 THAILAND HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 190 TAIWAN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 TAIWAN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 192 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 193 TAIWAN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 TAIWAN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 TAIWAN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 TAIWAN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 TAIWAN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 199 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 200 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 201 TAIWAN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 203 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 204 SINGAPORE SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 SINGAPORE MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 206 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 207 SINGAPORE X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 208 SINGAPORE COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 SINGAPORE MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 SINGAPORE GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 SINGAPORE OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 213 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 214 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 215 SINGAPORE HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 218 PHILIPPINES SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 PHILIPPINES MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 220 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 221 PHILIPPINES X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 PHILIPPINES COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 223 PHILIPPINES MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 224 PHILIPPINES GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 PHILIPPINES OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 227 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 228 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 229 PHILIPPINES HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 231 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 232 VIETNAM SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 VIETNAM MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 234 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 235 VIETNAM X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 VIETNAM COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 VIETNAM MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 238 VIETNAM GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 VIETNAM OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 240 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 241 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 242 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 243 VIETNAM HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 REST OF ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 PRODUCT LIFELINE CURVE
FIGURE 9 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC MULTIPLE HEREDITY EXOSTOSIS MARKET, BY TYPE
FIGURE 15 RISING PREVALENCE OF GENETIC DISORDERS IS DRIVING THE GROWTH OF THE ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET FROM 2024 TO 2031
FIGURE 16 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET IN 2024 AND 2031
FIGURE 17 MARKET OVERVIEW
FIGURE 18 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2023
FIGURE 19 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2023
FIGURE 23 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2023
FIGURE 27 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2024-2031 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, CAGR (2024-2031)
FIGURE 29 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2023
FIGURE 31 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2024-2031 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, CAGR (2024-2031)
FIGURE 33 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2023
FIGURE 35 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 36 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 37 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2023
FIGURE 39 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 40 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 41 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC MULTIPLE HEREDITY EXOSTOSIS MARKET: SNAPSHOT (2023)
FIGURE 43 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
